Aurinia Pharmaceuticals Inc (AUPH)

[Zeppo]

Biotech has become a stock picker's universe instead of an industry wide advance.....that's for sure. Some shareholders bought this stock between $1 and 2$ just a few short months ago. Now even though many of these shareholders planned to stay in for the "long haul", the downside volatility has a % of them thinking about protecting profits instead. This is a normal series of events in biotech land. So if the P3 enrollment is strong and the testing is positive, other upside opportunities will present themselves. Human nature tells us that, after such an unusually steep rise in the stock price off a P2 test, some shareholders are going to be satisfied with their gains and take their profits.